How is the FDA's stance influencing Moderna's mRNA flu vaccine prospects?

The FDA’s openness toward Moderna’s flu vaccine ahead of an advisory meeting signals growing confidence in the company’s mRNA platform. A favorable tone could validate mRNA’s role in seasonal respiratory vaccines, potentially narrowing the performance gap between new mRNA flu shots and traditional egg-based vaccines.